These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38514384)

  • 1. During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range.
    Pulkkinen MA; Varimo TJ; Hakonen ET; Hero MT; Miettinen PJ; Tuomaala AK
    Diabetes Obes Metab; 2024 Jun; 26(6):2431-2438. PubMed ID: 38514384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single-centre real-world study.
    Eviz E; Killi NE; Karakus KE; Can E; Gokce T; Yesiltepe Mutlu G; Hatun S
    Diabet Med; 2024 Aug; 41(8):e15333. PubMed ID: 38671595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies.
    Schiaffini R; Lumaca A; Martino M; Rapini N; Deodati A; Amodeo ME; Ciampalini P; Matteoli MC; Pampanini V; Cianfarani S
    Diabetes Metab Res Rev; 2024 Jul; 40(5):e3826. PubMed ID: 38824455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes.
    Ng SM; Wright NP; Yardley D; Campbell F; Randell T; Trevelyan N; Ghatak A; Hindmarsh PC
    BMC Med; 2024 Apr; 22(1):175. PubMed ID: 38659016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks.
    Pulkkinen MA; Varimo TJ; Hakonen ET; Harsunen MH; Hyvönen ME; Janér JN; Kiiveri SM; Laakkonen HM; Laakso SM; Wehkalampi K; Hero MT; Miettinen PJ; Tuomaala AK
    Diabetes Technol Ther; 2023 Feb; 25(2):100-107. PubMed ID: 36511831
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study.
    Passanisi S; Salzano G; Bombaci B; Minuto N; Bassi M; Bonfanti R; Scialabba F; Mozzillo E; Di Candia F; Monti S; Graziani V; Maffeis C; Piona CA; Arnaldi C; Tosini D; Felappi B; Roppolo R; Zanfardino A; Delvecchio M; Lo Presti D; Calzi E; Ripoli C; Franceschi R; Reinstadler P; Rabbone I; Maltoni G; Alibrandi A; Zucchini S; Marigliano M; Lombardo F;
    Diabetes Care; 2024 Jun; 47(6):1084-1091. PubMed ID: 38626260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod
    DeSalvo DJ; Bode BW; Forlenza GP; Laffel LM; Buckingham BA; Criego AB; Schoelwer M; MacLeish SA; Sherr JL; Hansen DW; Ly TT
    Diabetes Technol Ther; 2024 Jun; 26(6):383-393. PubMed ID: 38277156
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
    Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
    Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.
    Rapini N; Martino M; Arnaldi C; Deodati A; Anagnostopoulou L; Amodeo ME; Ciampalini P; Pampanini V; Lorubbio A; Tosini D; Cianfarani S; Schiaffini R
    Front Endocrinol (Lausanne); 2024; 15():1382920. PubMed ID: 38836230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-Month Effectiveness of Advanced
    Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
    Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, Safety, and Metabolic Control Among Danish Children and Adolescents with Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems.
    Fagerberg AR; Borch L; Kristensen K; Hjelle JS
    Diabetes Technol Ther; 2024 May; 26(5):287-297. PubMed ID: 38386435
    [No Abstract]   [Full Text] [Related]  

  • 13. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
    Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
    Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
    [No Abstract]   [Full Text] [Related]  

  • 14. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
    Henry Z; Villar Fimbel S; Bendelac N; Perge K; Thivolet C
    Diabetes Obes Metab; 2024 Feb; 26(2):557-566. PubMed ID: 37905353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: A retrospective analysis.
    Petruzelkova L; Jiranova P; Soupal J; Kozak M; Plachy L; Neuman V; Pruhova S; Obermannova B; Kolouskova S; Sumnik Z
    Pediatr Diabetes; 2021 Jun; 22(4):594-604. PubMed ID: 33576551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial.
    McAuley SA; Lee MH; Paldus B; Vogrin S; de Bock MI; Abraham MB; Bach LA; Burt MG; Cohen ND; Colman PG; Davis EA; Hendrieckx C; Holmes-Walker DJ; Kaye J; Keech AC; Kumareswaran K; MacIsaac RJ; McCallum RW; Sims CM; Speight J; Stranks SN; Sundararajan V; Trawley S; Ward GM; Jenkins AJ; Jones TW; O'Neal DN;
    Diabetes Care; 2020 Dec; 43(12):3024-3033. PubMed ID: 33055139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes.
    Bassi M; Patti L; Silvestrini I; Strati MF; Ponzano M; Minuto N; Maggi D
    Front Endocrinol (Lausanne); 2023; 14():1099024. PubMed ID: 36777356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.
    Forlenza GP; Pinhas-Hamiel O; Liljenquist DR; Shulman DI; Bailey TS; Bode BW; Wood MA; Buckingham BA; Kaiserman KB; Shin J; Huang S; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2019 Jan; 21(1):11-19. PubMed ID: 30585770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.